Juan Lara

Experience

• 

  COFEPRIS

  Feb 2016 - Aug 2017

  Professional Internship and Social Service

  I reviewed and granted applications to obtain or modify the health license to sell and distribute medicines and medical devices.I learned how to use Mexican legal instruments such as the General Health Law, its regulations, the Mexican pharmacopoeias, their respective supplements, and as well as official Mexican standards such as NOM-059, NOM-164, NOM-072, NOM-073, NOM-220, NOM-177.

• 

  COFEPRIS

  Mar 2018 - May 2019

  I developed and implemented a process of total traceability of the reviewing process of new drugs, modifications and extensions applications to achieve the sale and marketing authorization, as well as certificates of free sale in order to comply with regulatory times.I led an inventory project of the marketing authorization applications and over-the-counter certificates in which I oversaw 4 full-time employees and over 30 temporary workers. I developed the technical agenda of the event named the "Second International Week of Regulatory Science and Good Regulatory Practices (SSI)" which assisted more than 600 attendants.I was a lecturer on the topic "Good Practices of Submission and Good Review Practices", at the event "National Meeting of Good Registration Management: APEC, ICH and WHO Guidelines".

  • Chemist Reviewer

    Jan 2019 - May 2019

  • Documentation Chemist Center for Innovation in Regulatory Science

    Mar 2018 - Dec 2018
• 

  IQVIA

  Feb 2020 - Jun 2021

  Consulting Analyst

  I supported the development of consulting projects for pharmaceutical industries to support their understanding of issues such as market access in Latin American countries, pricing strategies and optimization of pharmaceutical sales forces.

• 

  CIRS - Centre for Innovation in Regulatory Science

  Jun 2021 - now

  Support in the development of regulatory research projects aimed to optimizing and strengthening drug regulatory agencies, for example: 1. Benchmarking studies of regulatory review times for the approval of new active substances in reference agencies 2. Assessments of the implementation and adherence to the ICH Guidelines in participating regulatory agencies of the ICH 3. Evaluations of the regulatory framework and performance of specific agencies, including special topics such as public access to new active substances, orphan drugs, and innovative therapies 4. Assessments of the current state of reliance activities in Latin America Show less

  • Senior Research Analyst

    May 2023 - now

  • Research Analyst

    Jun 2021 - May 2023